ebitda

Approved the Bionaturis Group Capital Increase for a maximun of up to 579.129 new shares

The purpose is to finance the Group’s growth through the acquisition of a pharmaceutical laboratory, increasing the integration in the value chain as well as its services portfolio to third parties and the number of international clients.

After the acquisition Bionaturis Group would have a global turnover over €8 Million in the year 2016, with an EBITDA’s operating margin about 30% and employing more than 60 workers, strengthening the Group’s industrial structure.

The Company carried out another capital increase operation last April 2014 for an amount worth of €3 Million with 76% of oversubscription.

Jerez, on June 2, 2015. The Alternative Equity Market (MAB) Governing Body has approved the Document of Capital Increase (Spanish DAM) presented by Bionaturis Group in order to formalize the capital increase operation authorized by its Board of Directors last May, 14 2015. This capital increase aims to stimulate the Company’s growth process by financing the acquisition of the entire capital share of a laboratory that manufactures exclusively to third parties (Contract Manufacturing Organization).

The capital increase, that retains the preferential subscription right, involves the issue of a maximum of up to 579,129 new shares, with the same class and rights, with a par value of €0,05 per share, and a share premium of €6,95 per share. Furthermore, it was agreed to offer the new shares at a ratio of 1 new share for every eight old, free of issue expenses.

Currently the Company has a share capital of €231,651,8 consisting of 4,633,036 shares with a par value of €0,05 per share.

If the increase fully subscribes, the final share capital will be €260,608,25, divided amongst 5,212,165 shares with a par value of €0,05 each one.

The new issued shares will trade in MAB as soon as […]

June 2nd, 2015|Blog english, Press Releases|Comments Off|

Bionaturis 2013 annual report

Bionaturis (BNT-MAB), an international reference company developing biological drugs, has released the 2013 Annual Report.

Victor Infante, Bionaturis’ CEO, has commented about the results: “The important point here is that our performance supports our strategy. Now the focus is on the internationalization process and to achieve the milestones needed to move forward our BNT programs to the market. We are on the right track. We keep estimations to increase our revenues around 400% this year”.

The 2013 annual report goes over the main milestones achieved during 2013 and the outlook for 2014 and beyond.

Key figures

Revenue for 2013 was €1.75 million as compared to €1.4 million for 2012, an increase of €0.35 million, or 25%. Net sales for 2013 was €0.89 million as compared to €0.44 million for 2012, an increase of 96%.

In 2013 EBITDA was €721 thousand as compared to €-246 thousand for 2012, an increase of €+ 967 thousand. In 2013 Net Result was €473 thousand as compared to €-342 thousand for 2012, an increase of €815 thousand.

Click here to get the full report

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR